Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INSURE extension study of AIN457 for non-infectious posterior-segment uveitis
2009-015509-38Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-infectious intermediate uveitis, Posterior uveitis (non-infectious) and non-infectious panuveitis (NIU) comparing AIN457 with Placebo (2 arms). Primary endpoint: Primary efficacy endpoint. Started Jul 2010; status: completed.
02
Drugs
secukinumab
03
Conditions
non-infectious intermediate uveitisPosterior uveitis (non-infectious)non-infectious panuveitis (NIU)
Beyond the preview
Go deeper on 2009-015509-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015509-38.